Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20025709 | 0.88 | KDM1A (0.73) | KDM1A | |
| SCHEMBL20604586 | 0.84 | KDM1A (0.77) | KDM1A | |
| SCHEMBL20843800 | 0.78 | KDM1A (0.71) | KDM1A | |
| SCHEMBL20843876 | 0.77 | KDM1A (0.84) | KDM1A | |
| SCHEMBL20843832 | 0.76 | KDM1A (0.83) | KDM1A | |
| SCHEMBL20025743 | 0.75 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20025684 | 0.75 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20604661 | 0.75 | KDM1A (1.00) | KDM1A | |
| SCHEMBL22359970 | 0.75 | KDM1A (0.74) | KDM1A | |
| SCHEMBL20843803 | 0.75 | KDM1A (0.80) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.